Long-term follow-up for EVEROLD study patients
Part of Immune system & allergy clinical trials.
This trial follows patients who completed the EVEROLD study to collect long-term health data. It is an observational study that does not test a new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You participated in the EVEROLD study before
- You have completed the 12-month check-up visit for the EVEROLD study
- You agree to join this observational follow-up study
- You do not object to the use of your medical data
- You are not under legal guardianship or protection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study checks kidney transplant outcomes and care over many years by using your existing medical records. It may help researchers understand what happens to transplant patients at 5 and 10 years and improve future follow-up.
This study checks long-term health and well-being in people who previously joined a lung transplant research study. It may help doctors understand long-term changes after transplant and improve future care.
This study looks at the long-term health of people who took part in the EXCELLENT trial. If you finished that trial within the last 10 years, you may be able to join this study to help researchers understand how participants are doing over time.
This Phase 1 study is a follow-up “rollover” for people who already completed the 12-month visit of an earlier study. It checks what happens next after that prior study and may help doctors understand the ongoing safety and effects of the treatment.
This is a follow-up study for people who already participated in the STEPS research project about improving fairness in organ transplants. Researchers want to track how participants are doing over time and learn more about transplant outcomes.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Hear when a new Transplant; Complication, Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.